Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
Laura Prendergast

Laura Prendergast Analyst Performance

Managing Director- Biotech Equity Research at Stifel Nicolaus

Laura Prendergast is a stock analyst at Stifel Nicolaus in the healthcare sector, covering 13 publicly traded companies. Over the past year, Laura Prendergast has issued 21 stock ratings, including and buy recommendations. While full access to Laura Prendergast's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Laura Prendergast's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
28 Last 1 Years
Buy Recommendations
91.30% 21 Buy Ratings
Companies Covered
13 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy91.3%21 ratings
Hold8.7%2 ratings
Sell0.0%0 ratings

Out of 23 total stock ratings issued by Laura Prendergast at Stifel Nicolaus, the majority (91.3%) have been Buy recommendations, followed by 8.7% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
13 companies

Laura Prendergast, an analyst at Stifel Nicolaus, currently covers 13 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
13 companies
100.0%

Laura Prendergast of Stifel Nicolaus specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
13 companies
100.0%

Laura Prendergast's Ratings History at Stifel Nicolaus

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
10/23/2026Set Price Target$23.93$55.00
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
10/14/2026Initiated Coverage$34.26$48.00Buy
Immatics N.V. stock logo
IMTX
Immatics
10/13/2026Initiated Coverage$6.83$15.00Buy
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
10/1/2026Set Price Target$2.80$5.00
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
9/14/2026Lower Price Target$10.22$30.00Buy
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
9/9/2026Boost Price Target$210.36$230.00Buy
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
9/9/2026Lower Price Target$8.20$15.00Buy
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
8/7/2026Set Price Target$24.15$48.00Buy
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
4/27/2026Boost Price Target$25.75$40.00Buy
Erasca, Inc. stock logo
ERAS
Erasca
4/27/2026Boost Price Target$21.49$30.00Buy
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4/20/2026Reiterated Rating$148.63Buy
Erasca, Inc. stock logo
ERAS
Erasca
3/10/2026Set Price Target$15.58$20.00
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
3/9/2026Boost Price Target$16.95$24.00Buy
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
2/11/2026Initiated Coverage$23.37$48.00Buy
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
2/10/2026Initiated Coverage$10.84$23.00Buy
Erasca, Inc. stock logo
ERAS
Erasca
1/12/2026Set Price Target$6.23$10.00
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
12/3/2025Initiated Coverage$9.57$15.00Buy
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
12/3/2025Initiated Coverage$4.44$12.00Buy
Nuvalent, Inc. stock logo
NUVL
Nuvalent
11/17/2025Boost Price Target$110.17$135.00Buy
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
11/10/2025Upgrade$33.30$40.00Buy
Erasca, Inc. stock logo
ERAS
Erasca
11/6/2025Set Price Target$2.25$6.00
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10/16/2025Initiated Coverage$92.75$115.00Buy
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
10/15/2025Initiated Coverage$4.15$8.00Buy
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
10/15/2025Initiated Coverage$49.56$85.00Buy
Erasca, Inc. stock logo
ERAS
Erasca
10/15/2025Initiated Coverage$2.49$4.00Buy
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
10/15/2025Initiated Coverage$16.57$16.00Hold
Erasca, Inc. stock logo
ERAS
Erasca
3/26/2025Initiated Coverage$1.48$5.00Outperform
Third Harmonic Bio, Inc. stock logo
THRD
Third Harmonic Bio
2/11/2025Reiterated Rating$4.65Market Perform